Efficacies of liposome-encapsulated enrofloxacin against Staphylococcus aureus infection in Anatolian shepherd dog monocytes in vitro

Basit Öğe Kaydı
dc.contributor.authorBas, AL
dc.contributor.authorSimsek, A
dc.contributor.authorErganis, O
dc.contributor.authorCorlu, M
dc.date.accessioned2020-03-26T16:57:06Z
dc.date.available2020-03-26T16:57:06Z
dc.date.issued2005
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the intracellular activity of two types of liposome-encapsulated enrofloxacin (LE) compared with free enrofloxacin and non-treated control against Staphylococcus aureus, phagocytosed by monocytes in healthy Anatolian Shepherd dogs. Enrofloxacin was encapsulated with two different types of liposome in multilamellar large vesicles (MLV). Type A MLV were composed of 15 mg phosphatidylcholine and 35 mg cholesterol, Type B MLV were composed of phosphatidylcholine, cholesterol and enrofloxacin in a molar ratio of 1:1:1. Intracellular activity was estimated by comparing the numbers of bacteria surviving intracellularly in monocytes exposed to free enrofloxacin and LE for 4 h at the doses of 0.25, 0.5 and 1 mu g/ml, with those surviving intracellularly in untreated control monocytes. All three forms of enrofloxacin (free, Type A and B liposomes) increased the intracellular killing of S. aureus in a concentration dependent manner. Comparison of 1 mu g/ml Type B LE revealed that killing activity was significantly higher than those of other concentrations. The results showed that LE was superior in reducing the number of intracellularly located bacteria compared to the free drug and control. The beneficial effect of liposomal encapsulation is presumably due to the fact that both liposomes and bacteria are localized at the same spot in phagocytic cells.en_US
dc.identifier.endpage223en_US
dc.identifier.issn0341-6593en_US
dc.identifier.issue6en_US
dc.identifier.pmid16028487en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage219en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/19716
dc.identifier.volume112en_US
dc.identifier.wosWOS:000231365600004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherM H SCHAPER GMBH CO KGen_US
dc.relation.ispartofDEUTSCHE TIERARZTLICHE WOCHENSCHRIFTen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectliposomeen_US
dc.subjectenrofloxacinen_US
dc.subjectAnatolian shepherd dogen_US
dc.subjectmonocyteen_US
dc.subjectStaphylococcus aureusen_US
dc.titleEfficacies of liposome-encapsulated enrofloxacin against Staphylococcus aureus infection in Anatolian shepherd dog monocytes in vitroen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu